Clinical risk factors for weight gain during psychopharmacologic treatment of depression: Results from 2 large german observational studies

Journal of Clinical Psychiatry

Volumn 76, Issue 6, 2015, Pages e802-e808

  Kloiber, Stefan ^a   Domschke, Katharina ^b   Ising, Marcus ^a   Arolt, Volker ^c   Baune, Bernhard T ^d   Holsboer, Florian ^a   Lucae, Susanne ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BODY MASS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GERMANY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT DURATION; WEIGHT GAIN; DEPRESSION; DRUG EFFECTS; PSYCHOLOGY; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; BODY MASS INDEX; DEPRESSION; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; WEIGHT GAIN;

EID: 84932632832     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09212     Document Type: Article

References (29)

1. Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord. 1984;7(2):133-138. doi:10.1016/0165-0327(84)90031-4 PubMed
2. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):37-41. PubMed
3. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37(3):193-220. doi:10.1016/S0022-3956(03)00018-9 PubMed
4. Rockwell WJ, Ellinwood EH Jr, Trader DW. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J. 1983;76(11):1407-1412. doi:10.1097/00007611-198311000-00021 PubMed
5. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277-288. doi:10.1016/S0165-1781(01)00234-7 PubMed
6. Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: a review. Obes Rev. 2004;5(2):115-121. doi:10.1111/j.1467-789X.2004.00139.x PubMed
7. Rana JS, Nieuwdorp M, Jukema JW, et al. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9(3):218-232. doi:10.1111/j.1463-1326.2006.00594.x PubMed
8. Paykel ES. Depression and appetite. J Psychosom Res. 1977;21(5):401-407. doi:10.1016/0022-3999(77)90049-6 PubMed
9. Kazes M, Danion JM, Grangé D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord. 1994;30(3):193-207. doi:10.1016/0165-0327(94)90080-9 PubMed
10. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229. doi:10.1001/archgenpsychiatry.2010.2 PubMed
11. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64(suppl 8):22-29. PubMed
12. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-1272. doi:10.4088/JCP.09r05346blu PubMed
13. Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med. 1979;41(7):535-544. doi:10.1097/00006842-197911000-00004 PubMed
14. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67(3):421-424. doi:10.4088/JCP.v67n0313 PubMed
15. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res. 1988;26(3):265-271. doi:10.1016/0165-1781(88)90120-5 PubMed
16. Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol. 2011;14(3):367-375. doi:10.1017/S1461145710000933 PubMed
17. Himmerich H, Schuld A, Haack M, et al. Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res. 2004;38(5):485-489. doi:10.1016/j.jpsychires.2004.02.002 PubMed
18. Heiskanen TH, Koivumaa-Honkanen HT, Niskanen LK, et al. Depression and major weight gain: a 6-year prospective follow-up of outpatients. Compr Psychiatry. 2013;54(6):599-604. doi:10.1016/j.comppsych.2013.02.001 PubMed
19. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62(4):321-326. doi:10.1016/j.biopsych.2006.10.001 PubMed
20. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009;43(3):215-229. doi:10.1016/j.jpsychires.2008.05.002 PubMed
21. Baune BT, Hohoff C, Berger K, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology. 2008;33(4):924-932. doi:10.1038/sj.npp.1301462 PubMed
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association; 1994.
23. Overall JE, Rhoades HM. Use of the Hamilton Rating Scale for classification of depressive disorders. Compr Psychiatry. 1982;23(4):370-376. doi:10.1016/0010-440X(82)90087-6 PubMed
24. Wittchen HU, Wunderlich U, Gruschwitz S, et al. SKID-I, Strukturiertes Klinisches Interview für DSM-IV. Göttingen: Hogrefe; 1997.
25. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5(4):437-440. doi:10.1016/0924-977X(95)00012-E PubMed
26. Wetterling T, Müssigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19(4):316-321. doi:10.1097/00004714-199908000-00006 PubMed
27. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry. 2003;64(8):883-889. doi:10.4088/JCP.v64n0805 PubMed
28. Pinar M, Gulsun M, Tasci I, et al. Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):135-139. doi:10.1016/j.pnpbp.2007.07.028 PubMed
29. Degenhardt EK, Jamal HH, Tormey S, et al. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. J Clin Psychopharmacol. 2011;31(3):337-340. doi:10.1097/JCP.0b013e3182196e64 PubMed